他莫昔芬的安全性。 - Suppr

Suppr

超能文献

Safety of tamoxifen.

作者信息

Patterson J S, Baum M

出版信息

Lancet. 1978 Jan 14;1(8055):105. doi: 10.1016/s0140-6736(78)90053-3.

DOI:10.1016/s0140-6736(78)90053-3

PMID:74554

Abstract

摘要

相似文献

Safety of tamoxifen.他莫昔芬的安全性。

Lancet. 1978 Jan 14;1(8055):105. doi: 10.1016/s0140-6736(78)90053-3.

Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer.他莫昔芬：乳腺癌治疗与预防过程中的毒性及耐药性

Annu Rev Pharmacol Toxicol. 1995;35:195-211. doi: 10.1146/annurev.pa.35.040195.001211.

Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.他莫昔芬治疗的乳腺癌患者白细胞中他莫昔芬-DNA加合物的测定

Chem Res Toxicol. 2004 Dec;17(12):1577-83. doi: 10.1021/tx049930c.

AFPep, a novel drug for the prevention and treatment of breast cancer, does not disrupt the estrous cycle or fertility in rats.AFPep是一种用于预防和治疗乳腺癌的新型药物，不会扰乱大鼠的发情周期或生育能力。

Oncol Rep. 2009 Jul;22(1):49-56. doi: 10.3892/or_00000405.

Use of tamoxifen for breast cancer: twenty-eight years later.他莫昔芬用于乳腺癌治疗：二十八年之后

J Clin Oncol. 1995 Feb;13(2):513-29. doi: 10.1200/JCO.1995.13.2.513.

Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells.抑制液泡 H+-ATP 酶通过上调乳腺癌细胞中 CHOP 增强对他莫昔芬的敏感性。

Biochem Biophys Res Commun. 2013 Aug 2;437(3):463-8. doi: 10.1016/j.bbrc.2013.06.106. Epub 2013 Jul 6.

Tamoxifen.

Rep Carcinog. 2011;12:393-6.

Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro.他莫昔芬与5-氟尿嘧啶治疗乳腺癌：体外细胞毒性协同作用

Cancer Res. 1983 Nov;43(11):5298-303.

The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells.抗精神病药物氯丙嗪增强了他莫昔芬对他莫昔芬敏感和他莫昔芬耐药的人乳腺癌细胞的细胞毒性作用。

Anticancer Drugs. 2009 Sep;20(8):723-35. doi: 10.1097/CAD.0b013e32832ec041.

A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.一种转移性乳腺癌细胞系GI-101A，雌激素受体呈阳性，对雌激素有反应，但对他莫昔芬耐药。

Cell Biol Int. 1998;22(6):413-9. doi: 10.1006/cbir.1998.0269.

引用本文的文献

Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.

Dig Dis Sci. 1995 Dec;40(12):2602-7. doi: 10.1007/BF02220448.

A risk-benefit assessment of tamoxifen therapy.他莫昔芬治疗的风险效益评估。

Drug Saf. 1993 May;8(5):381-97. doi: 10.2165/00002018-199308050-00005.

Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.

Breast Cancer Res Treat. 1981;1(1):59-68. doi: 10.1007/BF01807893.

Tamoxifen and liver damage.他莫昔芬与肝损伤。

Br Med J (Clin Res Ed). 1984 Aug 4;289(6440):288. doi: 10.1136/bmj.289.6440.288.

Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.雌激素和抗雌激素可刺激培养的人乳腺癌细胞释放骨吸收活性物质。

J Clin Invest. 1985 Feb;75(2):726-31. doi: 10.1172/JCI111753.

Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.托瑞米芬高剂量用于绝经后晚期乳腺癌患者的I期临床及药代动力学研究。

Cancer Chemother Pharmacol. 1992;30(3):174-8. doi: 10.1007/BF00686307.

Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.他莫昔芬：其药理特性及在乳腺癌治疗中的治疗应用综述。

Drugs. 1978 Jul;16(1):1-24. doi: 10.2165/00003495-197816010-00001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验